The CIM begins the study of biomarkers of aging and dementia

The Center for Molecular Immunology (CIM) held the Initiation Workshop of the study of Biomarkers of aging and dementia "EBED2023".

The research is being conducted jointly with the Cuban Neuroscience Center Geriatric Service of the Calixto García Hospital and ONEI, the latter supporting a study that was conducted in 2017 and called the Aging and Population Survey.

The research plans to include 1000 patients and will be carried out in the communities (beginning with the Plaza de la Revolución municipality, in the Capital) with subjects over 50 years of age -some of whom were part of the study-, who will be Questionnaires will be applied and blood samples will be taken to detect markers of immunosenescence, cellular senescence and dementia.

New CIM clinical trial in cancer

The Center for Molecular Immunology (CIM) started a new clinical trial in cancer. This is a phase I-II study with VSSP (nanoparticle with immunomodulatory function) in patients with metastatic renal carcinoma. The mechanism of action of this molecule is to decrease suppressor myeloid cells, which are an important escape mechanism from tumors.
The initial workshop focused its attention on the clinical protocol to follow and the relevance of clinical trials in the treatment of this type of kidney cancer, knowing that there is no therapeutic alternative for patients with this condition.
In principle, the Hermanos Ameijeiras Hospital is approved as a clinical site, although the intention is to later incorporate other research sites that include the National Institute of Oncology and Radiobiology, Calixto García, Minimal Access Surgery Center and Enrique Cabrera Hospital.

New clinical trials with NeuralCIM® in Alzheimer's, Stroke and Ataxia

Mild or moderate Alzheimer's clinical trial

The Center for Molecular Immunology (CIM) will begin the two clinical studies with NeuralCIM®. An investigation will be carried out in Havana under the title of "Evaluation of the efficacy and safety of the administration of NeuralCIM®/NeuralCIM®-Donepezil vs. Donepezil in patients with mild-moderate Alzheimer's disease”; and the other in the rest of the country, with the title "Evaluation of the effectiveness and safety of the nasal administration of NeuralCIM in patients with the phenotype of Alzheimer's disease mild-moderate amnestic variant."

The study to be developed in the capital (10 hospitals), will have its start workshop on February 24. As of that date, caregivers may call the contact numbers listed below, after assessment by the specialist in their Health Area, who will issue a remittance to the corresponding secondary care center according to their place of residence. home. The person in charge of the care unit will give the caregiver a turn to take the patient and he or she will be evaluated with a view to their possible inclusion in the trial.

The study to be carried out in the rest of the country (16 hospitals), already had its initiation workshop on January 20 and inclusion began in some sites. The procedure for recruiting potential participants to be included in the trial is the same as described above for Havana.

ICTUS Clinical trial

On February 16, the initiation workshop of the PHASE I-II Clinical Trial Evaluation of the Safety and effect of NeuroEPO in patients with Acute Cerebral Infarction (SErONICA) was held.

It will take place in four institutions in the capital: Carlos J. Finlay Hospital (main site), National Institute of Neurology and Neurosurgery (INN), Enrique Cabrera Hospital and Comandante Manuel Fajardo Hospital. The principal investigator of the study is Dr. Luisa Paz Sendin, a second degree specialist in Neurology, belonging to the Finlay Hospital.

In order to be assessed for inclusion in the study, you must go to one of the hospitals mentioned above, in less than 48 hours after the onset of symptoms compatible with a possible ischemic cerebrovascular disease. These symptoms are: sudden loss of vision in one or both eyes, sudden difficulty walking, loss of balance or coordination, sudden onset severe headache with no known cause, loss of strength in one half of the body (face, arm and leg on the same side), difficulty speaking and understanding language, loss of sensation or tingling in the middle of the body and sudden deviation of the corner of the mouth.

ATAXIA Clinical trial

On March 9, the initiation workshop of the phase III clinical trial, placebo-controlled, randomized and double-blind, should be held to evaluate the efficacy and safety of the nasal administration of NeuroEPO in adult patients with spinocerebellar ataxias (NESCA study), after after having obtained its approval by the Cuban regulatory agency (CECMED).

This investigation will be monitored by CENCEC. It will be developed in the following institutions in the province of Holguín (province with the highest prevalence of this disease): CIRAH (Center for Research and Rehabilitation of Hereditary Ataxias) which will serve as the main site and is attached to the Lucía Iñiguez Clinical Surgical Hospital Landín” from the same province; as well as at the "Arnaldo Milían Castro" Clinical Surgical Hospital in Villa Clara and the National Institute of Neurology and Neurosurgery (INN) in the Cuban capital. The principal investigator of the study is Dr. Cs. Luis Velázquez Pérez, second degree specialist in Neurophysiology and Neurology, founder of CIRAH and currently president of the Cuban Academy of Sciences.
To be evaluated for inclusion in the study, one must go to one of the clinical sites mentioned above and in consultations that will be set up and have clinical, family and/or molecular elements of the variants of spinocerebellar ataxia that prevail in our country. This will allow researchers to include patients who meet the inclusion criteria and of course do not have exclusion criteria. This degenerative disease of the central nervous system has a hereditary and familial component and is characterized by disorders of gait, language, movement coordination, among other symptoms and signs. It is expected that, with NeuroEPO, a slowing down of the progression of this disease will be achieved, which today does not have drugs for its cure and/or slowing down its progression.

*After the initiation workshop, the contact details for inquiries will be published on the institutional channels of the CIM or they can be requested through the institutional mail.

Signing of the Agreement of Intent for Cuba-China scientific collaboration

In an official ceremony on October 1, within the framework of the anniversary of the constitution of the People's Republic of China, the Agreement of Intent for scientific collaboration was signed between the Center for Molecular Immunology, the Cuban-China Biotech Pharmaceutical joint venture and the Government from Changzhi city.

NeuralCIM clinical strategy update

The clinical strategy of the NeuralCIM is currently going through the stage of patient classification for inclusion in the phase 3 clinical trial in mild or moderate Alzheimer's, a study that will be carried out in Havana, once the patient diagnosis process is completed.
For its part, the training workshop on neuropsychological scales applied to Alzheimer's was held, with doctors and researchers from all the provinces of the country, where consultations will soon begin to classify patients for inclusion in the phase 4 clinical trial with NeuralCIM.
The data to request an appointment for the evaluation consultation of the phase 4 clinical trial will be published in the coming days on our website and institutional social networks.

Representation of the Cuban oncology community in ESMO2022

The European Congress of Oncology ESMOESMO - European Society for Medical Oncology is attended by Dr. Tania Crombet, Clinical Director of the CIM, renowned researchers and oncologists from our country, with the presentation of the most innovative clinical results of the CIMAvax_EGF vaccine.
A unique opportunity to position our science, learn about the state of the art in cancer studies and exchange with scientists from all over the world.

Clinical trial: "Safety and effect of ior®EPOCIM in patients convalescing from SARS-CoV-2 infection with cardiovascular, renal and/or respiratory sequelae"

A study is being carried out to evaluate the safety and effect of the drug ior®EPOCIM (produced by the Center for Molecular Immunology), in the treatment of post-COVID-19 convalescent patients with cardiovascular, renal and respiratory sequelae. Cuban subjects of any sex, aged 19 or older, who have suffered from COVID 19 (confirmed by PCR) and who 2 or 3 months later and to date present manifestations such as: Chest pain, rhythm fast heartbeat; Shortness of breath (especially on exertion), cough, difficulty climbing a ladder or hill, difficulty walking long distances; Changes in urine (foamy or bloody urine, more or less urine than usual, or needing to get up at night to urinate), fatigue (feeling more tired and have less energy than usual), dry skin and itching, swelling of the hands or feet, bags around the eyes (especially in the morning), shortness of breath, lower back pain, high blood pressure, poor appetite or nausea and vomiting, difficulty concentrating, trouble concentrating sleep cramps at night.

Diagnosis of these sequelae will be confirmed by computerized axial tomography or other cardiovascular or respiratory function tests, as directed by the study physician. Pregnant or lactating women, or subjects with a history of thromboembolic disease in the last 3 to 6 months, or a history of serious chronic or life-limiting diseases, or who are receiving dialysis or hemodialysis treatment, or have received treatment with an investigational product in the last 6 months. Subjects with mental incapacity that prevents them from understanding the research, signing the participation consent document and complying with the treatment scheme and the evaluations provided for in the study may not be included either.

Two treatment groups will be formed. A group called the "control group" will receive treatment with only conventional therapy. This may include respiratory physiotherapy or other drugs that, according to the doctor's criteria, may be used to treat the cardiovascular, renal or respiratory sequelae under study. The other group called "study group", in addition to conventional therapy will receive 5 administrations of ior®EPOCIM. Subjects are assigned to one or another treatment group by personnel who are not involved in the research, so all subjects will have an equal chance of receiving one treatment or another.
For more information go to:
Province Place where the study consultation is carried out (sites already included) To contact
Havana Hospital October 10
Ground floor of the Mella Pavilion in the Physiotherapy Room Monday-8:30 am-12:00 m
Dr. Yulmys Rodríguez Borges, Physiatry Consultation,
Dr. Abdel del Busto Mesa
Phone: 78776267, ext 261
Pinar del Río Hospital Abel Santamaría 2nd and 4th Monday: Dr. Yusleny Sánchez Orta, Pulmonology
3rd Wednesday. Dr. Yoima González Pérez, Control Consultation 3, Hospital Abel Santamaría
Tuesday morning: Dra. Arlety Pita Valdés, Control Consultation 3, Hosp. Abel Santamaria
Phone 48 762068
Cienfuegos Hospital Gustavo Aldereguía Lima, CEA Tuesday, 8:00 am-12:00 m
General evaluation consultation, every day
Consultation of the CIs:
Lic. Yuleidis García Rodríguez
Lic. Karelia Cortina Naples
Dr. Julio Jova Duenas
Dr. Annia Hernandez Marin
Phone: 43591751
Villa Clara Hospital Arnaldo Milián Lic. Margarita Ríos Cabrera
Dr. Ignacio Ramirez Gomez
Phone: 42 270038
Camaguey Manuel Ascunce Domenech Hospital, Clinical Trials Department (in the basement) Thursday- 9:00 am-12:00 pm
Lic. Judith Ojeda de Pedro
Lic. Yaneidys Lores Méndez
Dr. Yanara Nélida Peláez Guevara
Phone: 32 253856
Holguin Vladimir Ilich Lenin Hospital,
EC Department 1st and 3rd Thursday of each month, 9:00 am
Lic. Kenya Garces Avila
Dr. Irmary Riverón Proenza
Phone: 24 461601
Guantanamo Agostinho Neto Hospital
Clinical Trials Consultation Thursday- 1:00 pm-4:00 pm
Mr. Yadyleidis Elias Oquendo
Lic. Cecilia Sayoux Thaureaux
Dr. Anais González Jarrosay
Dr. Yanet Blanco Robles
Phone: 21 387319
Santiago de Cuba Polyclinic of Specialties attached to the Saturnino Lora Hospital, Clinical Trials Consultation, 3rd Floor, Door 6 Friday, 9:00 am-12:00 m
Dr. Eduardo Rivero Rosales
Lic. Aymara Rosdo
Dr. Juan Carlos Sanchez Moraguez
Phone: 22 645447

Clinical trial: “Safety and effect of CIMAvax-EGF® in patients convalescing from SARS-CoV-2 infection with respiratory disorders”

Study group: treatment with CIMAvax-EGF® + support therapy
Control group: Only support therapy
Cuban subjects of any sex, older than 19 years of age, who after having had a PCR+, from 2 or 3 months (or more), present signs or symptoms of respiratory disorders will be included.
Frequent manifestations in case of respiratory sequelae: Shortness of breath on exertion as well as difficulty walking long distances.
Patients with mild to moderate respiratory history (for example, bronchial asthma or COPD), compensated prior to PCR+, may be included.
Subjects may not be included if:
- Are pregnant or lactating women.
- Have a history of thromboembolic disease in the last 3 to 6 months.
- Receiving dialysis or hemodialysis treatment,
- Have a history of serious or life-limiting chronic diseases.
- Are receiving or have received any research product in the last 6 months.
- They present evident mental incapacity that prevents them from understanding and signing the consent to participate in the research, and acting accordingly.

Go to:

Province Place where the study consultation is carried out (sites already included) To contact

Havana Hermanos Ameijeiras Hospital
Session 1, Door 2 (in the basement entering through Belascoain)
Take a previous shift at Shift Control (entering through Calle Márquez González) Dra. Denenke Basanta Bergolla (2nd and 4th Mondays 9:00 am-12:00 m)
Dr. Ileidys Rodríguez (1st and 3rd Mondays 9:00 am-12:00 pm)
Dr. Aliuska Aguilar Sosa
Phone: 78765760
Hospital October 10
Ground floor of the Mella Pavilion in the Physiotherapy Room Monday-8:30 am-12:00 m
Dr. Yulmys Rodríguez Borges, Physiatry Consultation,
Dr. Abdel del Busto Mesa
Dr. Yisel Zaldivar Ocampo
Phone: 78776267, ext 261
Salvador Allende Hospital Dra. Yamilka Hernández Sánchez
Dr. Annia Duany
Phone: 78251863, 78744235
Cienfuegos Hospital Gustavo Aldereguía Lima, CEA Tuesday, 8:00 am-12:00 m
General evaluation consultation, every day
Consultation of the CIs:
Lic. Yuleidis García Rodríguez
Lic. Karelia Cortina Naples
Dr. Julio Jova Duenas
Dr. Annia Hernandez Marin
Phone: 43591751
Villa Clara Hospital Arnaldo Milián Lic. Margarita Ríos Cabrera
Dr. Ignacio Ramirez Gomez
Phone: 42 270038
Camagüey Hospital Manuel Ascunce Domenech, Department of Clinical Trials (in the basement) Thursday- 9:00 am-12:00 m
Lic. Judith Ojeda de Pedro
Lic. Yaneidys Lores Méndez
Dr. Oscar Cebrian Rodriguez
Phone: 32 253856
Holguin Vladimir Ilich Lenin Hospital,
EC Department 1st and 3rd Thursday of each month, 9:00 am
Lic. Kenya Garces Avila
Dr. Irmary Riverón Proenza
Phone: 24 461601
Guantanamo Agostinho Neto Hospital
Clinical Trials Consultation Thursday- 1:00 pm-4:00 pm
Mr. Yadyleidis Elias Oquendo
Lic. Cecilia Sayoux Thaureaux
Dr. Maria Antonia Taboada Vila
Dr. Yamila Tabío Ferreiro
Phone: 21 387319
Santiago de Cuba Polyclinic of Specialties attached to the Saturnino Lora Hospital, Clinical Trials Consultation, 3rd Floor, Door 6 Friday, 9:00 am-12:00 m
Dr. Eduardo Rivero Rosales
Lic. Aymara Rosado/Lic. Yaquelin
Dr. Juan Carlos Sanchez Moraguez
Phone: 22 645447

The CIM joins the massive pediatric vaccination campaign

Our Center once again joins the vaccination campaign, this time in pediatric age. For this, in record time, with the help of all the areas of Services, Human Resources, doctors and certified nurses of the Center, all the conditions of a pediatric vaccination were created.
At the same time, we have received the collaboration of Gabi & Sofi and La Colmenita de Cuba, who will complement this process to make this experience an unforgettable moment for the children of our workers and the community.

The CDRs award the CIM the ¨Premio del Barrio¨

Our Center receives the ¨Premio del Barrio¨ from the hands of its National Coordinator Gerardo Hernández Cordelo. A recognition based on the CIM's contribution to Cuban health in its more than 25 years of scientific and technological work.
At the same time, the participation of workers from the Center in the confrontation with COVID19, integrating the Henry Reeve Brigades, was recognized.
Support for the vaccination of adults and pediatrics in the community was also recognized, in the CIM certified vaccinations and the promotion of community projects with primary schools for health promotion and care for vulnerable neighborhoods such as La Cantera.